Suchergebnisse - "Hsu, Ann"

PubPharm (8)

1

Estimation of serum-free 50-percent inhibitory concentrations for human immunodeficiency virus protease inhibitors lopinavir and ritonavir

enthalten in: Antimicrobial agents and chemotherapy | 2004

von Hickman, D. | Vasavanonda, S. | Nequist, G. | +5

2

Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine

enthalten in: The Journal of infectious diseases | 2004

von Kempf, D. | King, M. | Bernstein, B. | +7

3

Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children

enthalten in: The Pediatric infectious disease journal | 2003

von Sáez-Llorens, X. | Violari, A. | Deetz, C. | +17

4

Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients

enthalten in: Antimicrobial agents and chemotherapy | 2003

von Hsu, A. | Isaacson, J. | Brun, S. | +11

5

Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremia

enthalten in: Antimicrobial agents and chemotherapy | 2002

von Shulman, N. | Zolopa, A. | Havlir, D. | +9

6

Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients

enthalten in: The Journal of infectious diseases | 2002

von Benson, C. | Deeks, S. | Brun, S. | +17

7

enthalten in: Clinical pharmacokinetics | 1998

von Hsu, A. | Granneman, G. | Bertz, R.

8

enthalten in: Clinical pharmacokinetics | 1998

von Hsu, A. | Granneman, G. | Bertz, R.

1
[1]